Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool

Martina Mandarano 1*, Guido Bellezza 1, Maria Laura Belladonna 2, Jacopo Vannucci 3, Alessio Gili 4, Ivana Ferri 1, Chiara Lupi 5, Vienna Ludovini 5, Giulia Falabella 1, Giulio Metro 6, Giada Mondanelli 2, Rita Chiarì 7, Lucio Cagini 3, Fabrizio Stracci 4, 5, Fausto Roila 4, Francesco Puma 3, Claudia Volpi 2 and Angelo Sidoni 1

1 Section of Anatomic Pathology and Histology, Department of Experimental Medicine, Medical School, University of Perugia, Perugia, Italy.
2 Section of Pharmacology, Department of Experimental Medicine, University of Perugia, Perugia, Italy.
3 Department of Thoracic Surgery, Medical School, University of Perugia, Perugia, Italy.
4 Section of Public Health, Department of Experimental Medicine, University of Perugia, Perugia, Italy.
5 Umbria Cancer Registry, Perugia, Italy.
6 Department of Medical Oncology, Santa Maria della Misericordia Hospital, Perugia, Italy.
7 Medical Oncology, Ospedali Riuniti Padova sud, Padova, Italy.

Indoleamine 2,3-dioxygenase 2 (IDO2) is an analog of the tryptophan degrading and immunomodulating enzyme indoleamine 2,3-dioxygenase 1 (IDO1). Although the role of IDO1 is largely understood, the function of IDO2 is not yet well-elucidated. IDO2 overexpression was documented in some human tumors, but the linkage between IDO2 expression and cancer progression is still unclear, in particular in non-small cell lung cancer (NSCLC). Immunohistochemical expression and cellular localization of IDO2 was evaluated on 191 formalin-fixed and paraffin-embedded resected NSCLC. Correlations between IDO2 expression, clinical-pathological data, tumor-infiltrating lymphocytes (TILs), immunosuppressive tumor molecules (IDO1 and programmed cell death ligand-1 – PD-L1 –) and patients’ prognosis were evaluated. IDO2 high expression is strictly related to high PD-L1 level among squamous cell carcinomas group (p = 0.012), to either intratumoral or mixed localization of TILs (p < 0.001) and to adenocarcinoma histotype (p < 0.001). Furthermore, a significant correlation between IDO2 high expression and poor non-small cell lung cancer prognosis was detected (p = 0.011). The current study reaches interesting knowledge about IDO2 in non-small cell lung cancer. The close relationship between IDO2 expression, PD-L1 increased levels, TILs localization and NSCLC poor prognosis, assumed IDO2 as a potential prognostic biomarker to be exploited for optimizing innovative combined therapies with immune checkpoint inhibitors.

Keywords: indoleamine 2,3-dioxygenase 2, non-small cell lung cancer, immunohistochemistry, biomarker, immunomodulator
INTRODUCTION

Lung cancer is one of the major causes of cancer-related morbidity and mortality across the globe, and non–small cell lung cancer (NSCLC) represents the majority of lung malignancies (1). In recent years, the treatment of NSCLC has been partly improved by the introduction of immunotherapies and, in particular, employing the FDA approved immune checkpoint inhibitors (2). However, only about 20% of these patients can benefit from this therapy, resulting in the need for new biomarkers both to amplify the effect of immune checkpoint inhibitors and to identify new and more efficient therapeutic targets (3).

A large body of evidence indicates that tryptophan (Trp) metabolism is of paramount importance in cancer progression and for the increase of malignant properties of cancer cells (4–6). The immunoregulatory molecule indoleamine 2,3-dioxygenase 1 (IDO1)—which catalyzes the first, rate-limiting step of Trp degradation through the kynurenine (Kyn) pathway—is highly expressed in many types of human cancers (6, 7) and is generally associated with poor prognosis (8). Similarly, tryptophan 2,3-dioxygenase (TDO), which catalyzes the same reaction of IDO1, is expressed in a wide range of malignancies and has been shown to promote tumor progression and metastasis (9). Less is known about the third member of the Trp-degrading enzyme family, indoleamine 2,3-dioxygenase 2 (IDO2) (6). IDO1 and IDO2 are closely linked on chromosome 8 in humans, probably originating from an ancient gene duplication which occurred prior to the evolution of vertebrates (10, 11). Although characterized by a high level of sequence identity (11), IDO1 and IDO2 exhibit important functional differences, such as IDO2 being endowed with a very weak catalytic activity in vitro (12). Moreover, plasmatic levels of Trp and Kyn are similar in wild-type and Ido2−/− mice, suggesting that IDO2 is not as efficient as IDO1 or TDO in converting Trp to Kyn in vivo (13).

In tumors, IDO2 seems to be less frequently overexpressed than IDO1. Human gastric, colorectal, and renal carcinomas constitutively express both IDO1 and IDO2 (6, 14), as well as brain tumors, such as gliomas and meningiomas (15), and pancreatic ductal adenocarcinomas, in which IDO2 appears to be overexpressed (16).

However, despite the evidence of IDO2 expression in several types of malignancies, there are a limited number of studies about it in human tissues and its supposed functional role in the development and/or progression of cancer is still to be corroborated, in particular in NSCLC (6).

Recent studies showed that IDO1 is commonly expressed by NSCLC (17, 18) while there is still no evidence about its parologue IDO2.

Our purpose is to evaluate the level of IDO2 through its immunohistochemical expression in a series of resected NSCLCs, in order to assess its presence and localization in the tumor cells of this specific type of cancer. Moreover, we aim to unveil potential correlations between IDO2 expression, clinical-pathological parameters, immunosuppressive molecules of the tumor microenvironment and patients’ prognosis, in order to outline IDO2 as both a potential new biomarker for better patient risk stratification and as a possible target for the pharmacological treatment of NSCLC.

MATERIALS AND METHODS

Patient Selection

The study has been prepared according to ethical guidelines regarding the informed consent of the involved human participants (Number of Local Ethic Committee Decision: 2216/13 of CEAS Umbria).

Patients were recruited from the computer archive of the Institute of Anatomic Pathology and Histology, S. M. Misericordia Hospital, Perugia, Italy, involving all the NSCLC cases which underwent a surgical resection in the period from 2009 to 2015. Moreover, only the cases with both known clinical parameters (summarized in Table 1) and with a complete clinical follow-up until 31st December 2017 were considered. The cases in pathological stage IV, according to the 8th edition for cancer staging by the American Joint Committee on Cancer (AJCC), were not taken into account. Regarding the other stages of disease, we arranged the NSCLCs into two groups: a Stage I group, encompassing the stages from IA1 to IB, and a Stage II-III one, enclosing the stages from IIA to IIIB.

Histology and Immunohistochemistry

Surgical specimens were formalin-fixed (10% buffered formalin) and paraffin-embedded (FFPE). Sections of 4 μm were taken and placed on slides with a permanent positive charged surface, both to obtain the Hematoxylin and Eosin (H&E) stain and the Immunohistochemical (IHC) stains. The H&E stain was carried out using a Leica ST5020 Multistainer (Leica Microsystems), employing the kit ST Infinity H&E Staining System (Leica Biosystems). All the IHC stains (peroxidase immunoenzymatic reaction with development in diaminobenzidine) were obtained by employing the BOND-III fully automated immunohistochemistry stainer (Leica Biosystems). In particular, IDO2 immunohistochemical slides were carried out using a heat-induced antigen retrieval with the ready to use Bond™ Epitope Retrieval Solution 1 (Leica Biosystems, Catalog No: AR9961) for 20 min, primary antibody incubation for 15 min (IDO2, ThermoScientific, Cat# PA5-71696, RRID: AB_2717550, dilution 1:50) and the ready to use Bond™ Polymer Refine Detection System (Leica Biosystems, Catalog No: DS9800). Proper positive and negative controls were included.

Histological subtype was assigned based on H&E slides, according to 2015 World Health Organization (WHO) classification for lung tumors. Moreover, in line with the immunohistochemical expression both of TTF-1 (Agilent, Cat#M357501-2, RRID: AB_2801260; dilution 1:100; BOND-III fully automated immunohistochemistry stainer, Leica Biosystems) and p40 (ScyTek Laboratories, Cat#A00112-C, RRID: AB_2800554; dilution 1:50; BOND-III fully automated immunohistochemistry stainer, Leica Biosystems) poorly differentiated NSCLCs were classified as adenocarcinomas or as squamous cell carcinomas.
| Parameter | IDO2 low | IDO2 high | Total |
|-----------|---------|-----------|-------|
| Gender    |         |           |       |
| M         | 23      | 17        | 40    |
| F         | 8       | 15        | 23    |
| Age       |         |           |       |
| <68 years | 13      | 15        | 28    |
| ≥68 years | 18      | 17        | 35    |
| Smoking   |         |           |       |
| Current smokers | 13 | 17 | 30 |
| Former smokers | 16 | 16 | 32 |
| Never smokers | 2   | 12       | 14    |
| Relapse   |         |           |       |
| Yes       | 12      | 16        | 28    |
| No        | 19      | 16        | 35    |
| Exitus    |         |           |       |
| Yes       | 6       | 9         | 15    |
| No        | 25      | 20        | 45    |
| Stage     |         |           |       |
| Adc<sup>a</sup> stage | 122 | 64 |      |
| I         | 6       | 8         | 14    |
| II - III  | 4       | 8         | 12    |
| Sqcc<sup>b</sup> stage | 69 | 36 |      |
| I         | 7       | 26        | 33    |
| II - III  | 14      | 33        | 47    |
| Histotype |         |           |       |
| Adc<sup>a</sup> | 10 | 8        | 18    |
| Sqcc<sup>b</sup> | 21 | 30       | 41    |
| Adc<sup>c</sup> pattern | 122 | 64 |      |
| Other than solid | 6 | 6        | 12    |
| Solid     | 4       | 15        | 19    |
| TILs Density |         |           |       |
| Adc<sup>a</sup> | 122 | 64 |      |
| Low       | 5       | 8         | 13    |
| High      | 8       | 55        | 63    |
| Sqcc<sup>b</sup> | 69 | 36 |      |
| Low       | 12      | 34        | 46    |
| High      | 9       | 26        | 35    |
| TILs Localization |       |           |       |
| Adc<sup>a</sup> | 122 | 64 |     |
| Intratumoral | 4 | 6        | 10    |
| Peritumoral  | 5 | 71       | 76    |
| Mixed      | 4 | 49       | 53    |
| Absent     | 0 | 0        | 0     |
| Sqcc<sup>b</sup> | 69 | 36 |     |
| Intratumoral | 8 | 33       | 41    |
| Peritumoral  | 2 | 29       | 31    |
| Mixed      | 11 | 30       | 41    |
| Absent     | 0 | 0        | 0     |
Statistical Analysis
Categorical variables were presented as frequencies with row and column percentages. Patients were divided into a young and an elderly group, according to the cut-off age (68 years, corresponding to patients' median age) for analysis. Categorical variables were compared between the groups (IDO2 low or IDO2 high) using Chi-square test or Fisher's exact test as appropriate. Odds Ratio (OR) was estimated when association was statistically significant.

Other causes of death were regarded as competing risk events in the patients' end-point. The cumulative incidence function (CIF) was compared between groups using Gray's method and was shown on a plot (20). Analysis of disease free survival (DFS) and overall survival (OS) were evaluated using a Fine and Gray model (competing risks regression in Supplementary Material 1) (21).

Continuous variables were categorized and the proportional hazards assumption of categorical variables was verified using a log-minus-log plot.

A p-value (p) < 0.05 was considered as statistically significant. Statistical analyses were performed by STATA 15.1 (StataCorpLP, Collage Station TX, USA) (22).

RESULTS
Patients Series
Data about patients' series were shown in Table 1.

One hundred and ninety-one patients were eligible for the study. Patients were all Caucasian, the median age was 68 years (range 38–84), with a median follow-up period of 50 months (range 1–107 months). One hundred and thirty-seven (72%) patients were males; 175 (91%) were either current smokers or former smokers. Regarding the pathological staging classification, 101 cases (53%) belonged to stage I, whereas 90 (47%) patients were in stage II-III. Fifty-six (29%), 16 (8%) and 1 (0.5%) patients relapsed after surgery, presenting 1, 2, or 3 localizations, respectively. Moreover, 12 patients presented nodal metastasis, 10 of which with one or more that were synchronous and hematogenous. Sixty-four (34%) died from NSCLC (Table 1).

Pathological Findings
Data about pathological findings were summarized in Table 1.

Regarding histological characterization, the series was composed of 122 (64%) adenocarcinomas and 69 (36%) squamous cell carcinomas.

The most frequent predominant pattern of adenocarcinomas was the acinar (78%; 64%). Just over half of the adenocarcinomas (74%; 61%) belonged to stage I, whereas the majority of squamous cell carcinomas (42; 61%) were in stage II-III.

IDO2 Immunohistochemical Analysis
Concerning IDO2 evaluation, the majority of the tumors (160 cases, 84%) belonged to the high expression group of this molecule, both among adenocarcinomas (112; 92%) and among squamous cell carcinomas (48; 70%, Table 1).

Most of the tumors (158; 83%) presented a membrane reinforcement of the stain (Figure 1A), with only 19 (12%) of those cases presenting a focal IDO2 labeling. In addition, 17 (11%) cases presented simultaneous cytoplasmic stains (Figure 1B) and, among these, only one had diffuse IDO2 expression. Eighty (51%) of the cases with only membranous immunostaining (which were 77–96% adenocarcinomas and 3–4% squamous cell carcinomas) presented IDO2 expression on the basolateral side of the tumor cellular membrane, with a reinforcement of the stain at the interface between tumor and stromal tissue and without an apical immunolabel (Figure 1C).

Similarly, the immunostains presented a reinforcement at the interface between the tumor nest and healthy lung parenchima in 4 (6%) squamous cell carcinomas. Twenty cases (10%) also presented a nuclear pattern of staining (Figure 1D), most of which were in adenocarcinomas (19; 95%) seemed to highlight the nuclei of the cells. As for the peritumoral lung tissues, there was a constant IDO2 expression in bronchial epithelial cells, localized in their cytoplasm, with membrane reinforcement (Figure 1D); due to this aspect, we used this expression as an internal control for the labeling. We also found IDO2 in subepithelial bronchial glands with a diffuse pattern of staining.

In the lung parenchyma, IDO2 marked reactive pneumocytes close to tumor tissue and also intralveolar macrophages. In both cases there was a granular intracytoplasmatic staining.

Clinical-Pathological Associations
The IDO2 associations with clinical-pathological parameters were reported in Table 1.

IDO2 showed a high expression when associated with a specific NSCLC histotype: in fact, in our series its high expression was found especially in adenocarcinomas (p < 0.001; OR = 4.9).

There were no correlations between IDO2 expression and the other clinical-pathological parameters examined, although there was almost a statistically significant association (p = 0.068) with patients who died from NSCLC: 91% presented a high IDO2 expression.

Microenvironmental Associations
Data about associations between IDO2 and microenvironment molecules were shown in Table 1.

Interestingly, a high IDO2 expression correlated with high PD-L1 among the squamous cell carcinomas group (p = 0.012; OR = 6.2). On the other hand, among the adenocarcinomas group it was seen that the higher the expression of IDO2, the lower the expression of PD-L1 (p = 0.035; OR = 4.0).

There was no association between IDO1 and IDO2 expression, both in the adenocarcinomas and the squamous cell carcinomas groups.

It is worthy of note that among the adenocarcinoma subgroup, high IDO2 expression was associated with an intratumoral or mixed localization of the TILs (94 and 91% of the cases, respectively), in a statistically significant manner (p < 0.001; OR = 11.4). On the other hand, there was no association with IDO2 expression and TIL density, in either of the histotype groups.
Survival Analysis
The results concerning the survival analysis were displayed in Tables 2, 3.

Regarding the univariate analysis, the most relevant statistically significant associations were between the increased probability of death from NSCLC and high expression of both IDO2 (SHR 2.64, 95% Confidence Interval—CI—1.11–6.31, p = 0.028) and IDO1 (SHR 1.71, 95% CI 1.02–2.85, p = 0.041); these relationships persisted also in the multivariate analysis, which highlighted a greater probability of death for the patients with a tumor high expression of either IDO2 or IDO1 than the NSCLC with a low expression level of these molecules (SHR 2.94, 95% CI 1.28–6.77, p = 0.011 and SHR 1.64, 95% CI 1.12–2.76, p = 0.041, respectively; Table 2). In addition, regarding patients with a high tumor expression of IDO2, the probability of death within 36 months was roughly 18% compared to almost 7% for the group with a low expression of IDO2 (p < 0.001). This difference increased within 60 months (28 vs. 12%, respectively, p < 0.001; Figure 2).

Similarly, both in the univariate and in the multivariate analysis, either being a male patient or presenting a stage II-III of disease increased the probability of death from NSCLC (Table 2).

The histotype, age of the patient, smoking habits, expression of PD-L1, TILs density and TILs localization had no statistically significant correlations with the probability of death from NSCLC (Table 2).

Belonging to either the stage II-III group or the adenocarcinoma group increased the risk of recurrence in the present NSCLC series, both regarding the univariate (SHR 1.60 and 1.96; 95% CI 1.01–2.54 and 1.16–3.32; p = 0.044 and 0.012, respectively) and the multivariate analysis (SHR 1.92 and 2.31; 95% CI 1.20–3.09 and 1.35–3.96; p = 0.006 and 0.002, respectively), as reported in Table 3.

IDO2 and the other parameters considered showed no association with the DFS.

DISCUSSION
Little is known about the role of indoleamine 2,3-dioxygenase 2 (IDO2) and its implications both in normal lung tissue and in NSCLC. In this scenario, we examined IDO2 immunolabeling in 191 resected NSCLC cases, in order to better understand its expression in this cancer type and to determine its correlations
with clinical-pathological parameters, other immunomodulatory molecules and patients’ prognosis.

Unlike IDO1, the real IDO2 cellular function is poorly understood even today, in both normal and tumor cells. As a matter of fact, it seems to have no—or just low—enzymatic activity on tryptophan, so some other mechanisms could be involved to explain its putative role in the tumoral immunoescape (6, 11, 13, 14, 23–26).

Previous studies demonstrated a constitutive expression of only IDO2 mRNAs in human liver, small intestine, spleen, brain, thyroid, placenta, thymus, lung, kidney, colon, endometrium and tests, with a full length and functional transcript highlighted only for the placenta and brain (6, 27–29). Surprisingly we found, as an incidental observation, an almost constant immunohistochemical IDO2 staining of both the bronchial epithelium and peribronchial sub-epithelial glands. The continuous exposure of the airways, particularly the upper ones, to external stimuli could explain the induction of a putatively tolerogenic IDO2 in the abovementioned tissues, as happens in antigen presenting cells (APCs) or in B cells during either inflammatory or reactive states (25–28).

Furthermore, the IDO2 labeling of both reactive pneumocytes and alveolar macrophages, observed in the current study, seems to confirm the existence of an adjunctive mechanism triggering IDO2 expression under specific microenvironmental conditions, such as stress. Nevertheless, if the immunohistochemical expression corresponds to a functionally active IDO2 protein (6, 16, 29) in human lung tissues it would need further studies.
Another interesting and incidental finding is that 10% of NSCLCs presented a nuclear pattern of IDO2 staining in tumor cells. This was already observed in murine series regarding hepatocytes (13). Moreover, in a previous study (19) we reported a nuclear labeling for IDO1 in NSCLC. However, it is generally not known how these two molecules would act at nuclear level, but the observation that some tumors present a nuclear localization of both IDO1 and IDO2 may suggest a signal-transducing function (13, 30), something already noted about IDO1 (31).

Furthermore, the consistent percentage (83%) of NSCLC in our series with an intense membranous IDO2 immunolabeling might open the way to further studies about its correlation with adhesion molecules, such as those from the cadherin family. It is known how the latter are involved in epithelial-mesenchymal transition in an Aryl hydrocarbon Receptor (AhR)-kynurenine dependent manner (32, 33), and that the kynurenines are in turn the product of IDO1 enzymatic activity. On the other hand, it is also known that IDO2 is not expressed as a functional tryptophan-degrading enzyme (6), at least not in human cancer cells lines (14). As an alternative, other authors (29) have correlated the IDO2-dependent/tryptophan-independent activation of an inhibitory isofrom of immunoregulatory transcription factor NF-IL6 (LIP) to a potential IDO2 role in metastatization. Consequently, a difference between IDO1 and IDO2 activity may really exist. These findings could support either a direct role of IDO2 in cellular adhesion (13) or an indirect role in modulating other adhesion molecules, promoting tumor invasiveness and transition toward a mesenchymal and more aggressive phenotype. Regarding the correlation between this IDO2 localization and the patients’ prognosis, we did not find any statistically significant results. Furthermore, the majority of the NSCLCs with such an immunolabeling pattern were, interestingly, adenocarcinomas. Moreover, this histotype often (64%) has a basolateral staining of the tumor cells, possibly related to the presence of intracytoplasmic mucus, which is a characteristic of the adenocarcinoma, in particular of the most differentiated ones. In addition, a high IDO2 level was more frequently present in adenocarcinomas than in the squamous cell carcinoma subgroup, a finding that corroborates the strict relationship between this molecule and the specific microenvironment of this NSCLC histotype. Despite the fact that IDO2 action in adenocarcinomas and in adenocarcinoma patterns may differ from that of IDO1 (6, 11, 14, 17–19, 24–26), we could speculate about the existence of other immunosuppressive mechanisms induced by IDO2 in this NSCLC subgroup. An alternative splicing of IDO2 (6, 13) could explain the different localizations found and suggest the occurrence of a distinctive splicing induction under certain conditions, such as inflammatory states, or according to particular tumor histotype—adenocarcinomas—as above reported. Some authors suggest that IDO2 activation is related to specific microenvironmental conditions (13, 26, 34) in specific cell types (11, 25), such as the neoplastic ones in our study, which is consistent with its possible immunomodulatory role in either stress conditions or disease response (13, 25).

Interestingly, we found a high co-expression of both PD-L1 and IDO2 in the squamous cell carcinomas subgroup, further evidence that IDO2 expression occurs in cells displaying tolerance markers. Based on this finding, a dual combination NSCLC therapy, such as inhibitors of both PD-1/PD-L1 immune checkpoints and IDO2, might be hypothesized. Currently, the combination of immunoccheckpoint inhibitors and IDO1 hinderers has already been tested in ongoing clinical trials, with encouraging results in NSCLC patients (35, 36). This approach could be easily transposed into further researches targeting combination therapies including IDO2 inhibitors.

Moreover, the fact that high IDO2 expression is associated, among adenocarcinomas, with intratumoral and mixed localization of TILs could suggest a possible role for IDO2 as an immunomodulatory molecule. As a matter of fact, it is partly already known how IDO2 could be involved in B cell-mediated autoimmunity (23, 37) and may also influence Treg activation (37). Although in some murine models IDO2 has been associated with a potential pro-inflammatory role, particularly in autoimmune diseases (38), other authors showed that IDO2 contributions to inflammation, both in the context of cancer and autoimmune disorders, remains to be elucidated (38, 39). Moreover, Metz et al. (26) demonstrated an immune modulation role of IDO2, and distinguished its non-redundant contributions to inflammation. Consequently, the increased IDO2 expression in NSCLC could likely occur when the tumor cells are closely in contact with the inflammatory infiltrate, and could be interpreted as a tumor attempt to evade the immune system attack (40–43).

Furthermore, there is a strict correlation, never described before, between high IDO2 expression and a worse NSCLC outcome. Moreover, from the long follow-up period we highlighted an increasing difference in the probability of death between the patients belonging to the group with a high tumor expression of IDO2 and those belonging to the low
IDO1 is reported to be related to both immunosuppression and inflammatory responses, strictly depending on the surrounding microenvironment (31, 60), and its expression could relate to a wide spectrum of patients’ outcomes (61). Regarding IDO2, we could assume a similar role, resulting both in the induction of and in the resistance to the host’s immune system (13, 23, 26, 34, 37, 38, 60); consequently, IDO2 could be implicated either in delaying or promoting tumor aggressiveness, based on the highly fluctuating interactions with all of the other activated molecules of the tumor microenvironment (11, 13, 25, 26, 34). However, additional studies are needed to demonstrate this, since IDO1 and IDO2 seem to be functionally different (12, 13, 31, 60) and the biological relevance of IDO2 is not fully understood yet (60, 62).

On the other hand, encouraging evidence about the prognostic role of both IDO1 and PD-L1 in NSCLC has been found (19), as confirmed in the current study by the correlation between the IDO1 overexpression and the high probability of death from cancer. At the moment, we could suggest the immunohistochemical assessment of IDO2 together with the abovementioned molecules, in order to better stratify the risk of patients with NSCLC, assuming that more than one biomarker influences, in an independent manner, the outcome of these tumors.

The present study supports the idea that there is the need to combine multiple biomarker assays, due to the multifactorial and complex nature of cancer-immune interactions (63, 64).

To the best of our knowledge, this is the first study about IDO2 immunohistochemical expression in NSCLC. The close relationships found between IDO2 and other molecules in the NSCLC microenvironment, together with its potential prognostic implications, could open the way for the assessment of possible combined therapeutic strategies with IDO2 selective inhibitors, both by figuring new mechanisms out and by exploring new pharmacological tools for NSCLC. The objectives are both to overcome the existing drug resistances and to increase the number of patients who could benefit from immunotherapy in this cancer type. Due to the so far limited knowledge of IDO2 expression and cellular functions, further studies at a molecular level are required to make this promising molecule become a new biomarker for NSCLC.

DATA AVAILABILITY STATEMENT

The datasets analyzed in this article are not publicly available in order to respect the confidentiality and protection of patients’ data, in compliance with the processing of data covered and protected by the Italian Privacy Law and by the GDPR (General Data Protection Regulation, EU regulation no. 2016/679). However, requests for access to a properly anonymized dataset of the present article could be directed to MM, mandaranomartina@gmail.com.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Comitato Etico delle Aziende Sanitarie della Regione Umbria (CEAS Umbria), Regione Umbria Palazzo Broletto Floor 3, Via Mario Angeloni 61, 06124 Perugia, Italy. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

MM, GB, MB, CV, and AS conceived and designed the study. JV, LC, and FP provided the resected surgical specimens. IF and GF performed both the histological slides and the immunohistochemical stains. MM, GB, and AS performed the histopathological analysis. MM, GB, MB, CV, GMo, JV, RC, VL, GMe, and FR filed and analyzed data. AG, CL, and FS provided the follow up data and performed the statistical analysis. MM, GB, MB, and CV wrote the paper. All the authors edited and contributed to manuscript revision, giving the final approval for publication.

FUNDING

MM, GB, MB, and CV received a research grant from Fondazione Cassa Risparmio Perugia for the project entitled Validazione del catabolismo del triptofano come biomarker nei carcinomi polmonari non a piccole cellule, number of the project 2018.0413.021 RICERCA SCIENTIFICA E TECNOLOGICA. CV is, also, the P.I. of the PRIN 20155C2PP7 entitled IDO2, much more than a clone of IDO1: unveiling a new biological role for an ancient enzyme and of the PRIN 20173EAZZ2 entitled Linking tryptophan catabolism to amyotrophic lateral sclerosis: from the pathogenesis to the pharmacological treatment.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2020.00839/full#supplementary-material
REFERENCES

1. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/european thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. (2011) 6:244–85. doi: 10.1097/JTO.0b013e3182062221

2. Zimmermann S, Peters S, Owinoko T, Gadgeel SM. Immune checkpoint inhibitors in the management of lung cancer. Am Soc Clin Oncol Educ Book. (2018) 38:682–95. doi: 10.1200/EDBK_201319

3. Pu X, Wu L, Su D, Mao W, Fang B. Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance. BMC Cancer. (2018) 18:1082. doi: 10.1186/s12885-018-4499-5

4. Munn DH, Mellor AL. IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance. Trends Immunol. (2016) 37:193–207. doi: 10.1016/j.it.2016.01.002

5. Uyttenhove C, Pilotte L, Theate I, van den Eynde BJ. Tryptophan-degrading enzymes in tumoral immune resistance. Front Immunol. (2015) 6:34. doi: 10.3389/fimmu.2015.00034

6. van Baren N, van den Eynde BJ. Tryptophan-degrading enzymes in tumoral immune resistance. Front Immunol. (2014) 5:673. doi: 10.3389/fimmu.2014.00673

7. D’Amato NC, Rogers TJ, Gordon MA, Greene LI, Cochrane DR, Spoelstra V, et al. The immune system in cancer: a complex interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase. Am J Pathol. (2015) 187:1197–206. doi: 10.1016/j.ajpath.2015.06.009

8. D’Amato NC, Rogers TJ, Gordon MA, Greene LI, Cochrane DR, Spoelstra V, et al. The immune system in cancer: a complex interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase. Am J Pathol. (2015) 187:1197–206. doi: 10.1016/j.ajpath.2015.06.009

9. D’Amato NC, Rogers TJ, Gordon MA, Greene LI, Cochrane DR, Spoelstra V, et al. The immune system in cancer: a complex interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase. Am J Pathol. (2015) 187:1197–206. doi: 10.1016/j.ajpath.2015.06.009

10. D’Amato NC, Rogers TJ, Gordon MA, Greene LI, Cochrane DR, Spoelstra V, et al. The immune system in cancer: a complex interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase. Am J Pathol. (2015) 187:1197–206. doi: 10.1016/j.ajpath.2015.06.009

11. D’Amato NC, Rogers TJ, Gordon MA, Greene LI, Cochrane DR, Spoelstra V, et al. The immune system in cancer: a complex interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase. Am J Pathol. (2015) 187:1197–206. doi: 10.1016/j.ajpath.2015.06.009

12. D’Amato NC, Rogers TJ, Gordon MA, Greene LI, Cochrane DR, Spoelstra V, et al. The immune system in cancer: a complex interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase. Am J Pathol. (2015) 187:1197–206. doi: 10.1016/j.ajpath.2015.06.009

13. D’Amato NC, Rogers TJ, Gordon MA, Greene LI, Cochrane DR, Spoelstra V, et al. The immune system in cancer: a complex interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase. Am J Pathol. (2015) 187:1197–206. doi: 10.1016/j.ajpath.2015.06.009

14. D’Amato NC, Rogers TJ, Gordon MA, Greene LI, Cochrane DR, Spoelstra V, et al. The immune system in cancer: a complex interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase. Am J Pathol. (2015) 187:1197–206. doi: 10.1016/j.ajpath.2015.06.009
response in KRAS-driven sporadic pancreatic cancers. *Clinical Cancer Res.* (2019) 25:724–34. doi: 10.1158/1078-0432.CCR-18-0814

38. Merlo LMF Mandik-Nayak L. IDO2: a pathogenic mediator of inflammatory autoimmunity. *Clin Med Insights. Pathol.* (2016) 9 (Suppl. 1):21–8. doi: 10.4172/2059-9940.1000093

39. Prendergast GC, Metz R, Muller AJ, Merlo Lauren MF, Mandik-Nayak L. IDO2 in immunomodulation and autoimmune disease. *Front Immunol.* (2014) 5:585. doi: 10.3389/fimmu.2014.00585

40. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoeediting. *Annu Rev Immunol.* (2004) 22:329–60. doi: 10.1146/annurev.immunol.22.012703.104803

41. Brambilla E, Le Teuff G, Marguet S, Lantuejoul S, Dunant A, Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoeediting. *Annu Rev Immunol.* (2004) 22:329–60. doi: 10.1146/annurev.immunol.22.012703.104803

45. Thunnissen E, Allen TC, Adam J, Aisner DL, Beasley MB, Berczik AC, Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, Nakakubo Y, et al. Indoleamine 2,3-dioxygenase induced by IFN-γ and TNF-α as a potential biomarker of prostate cancer progression. *Front Immunol.* (2018) 9:1051. doi: 10.3389/fimmu.2018.01051

46. Zhang ML, Kem M, Mooradian MJ, Eliane JP, Huyhng TG, Iafalte AI, et al. Differential expression of PD-L1 and IDO1 in association with the immune microenvironment in resected lung adenocarcinomas. *Mod Pathol.* (2019) 32:511–23. doi: 10.1038/s41378-018-0160-1

47. Kim JW, Nam KH, Ahn SH, Park DJ, Kim HH, Kim SH, et al. Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. *Gastric Cancer.* (2016) 19:42–52. doi: 10.1007/s10120-014-0440-5

48. Karanikas V, Zamanakou M, Kerenidi T, Dahabreh I, Hevas A, Nakanou M, et al. Indoleamine 2,3-dioxygenase (IDO) expression in lung cancer. *Cancer Biol Ther.* (2007) 6:1258–62. doi: 10.4161/cbt.6.8.4446

49. de Jong RA, Toppen NL, Ten Hoor KA, Boezem HM, Kema JP, Hollema H, et al. Status of cellular immunity lacks prognostic significance in vulvar squamous carcinoma. *Gynecol Oncol.* (2012) 125:186–93. doi: 10.1016/j.ygyno.2011.12.416

50. Ricciuti B, Leonardi GC, Puccetti P, Fallarino F, Bianconi V, Sahebkar A, et al. Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence. *Pharmacol Ther.* (2019) 196:105–16. doi: 10.1016/j.pharmthera.2018.12.004

51. Schollbach J, Kircher S, Wiegeringer A, Anger F, Rosenwald A, Germer CT, et al. The local immune phenotype influences prognosis in patients with nodal-positive rectal cancer after neoadjuvant chemoradiation. *Int J Colorectal Dis.* (2020) 35:365–70. doi: 10.1007/s00384-019-03466-0

52. Lee YK, Lee HB, Shin DM, Kang MJ, Yi EC, Noh S, et al. Heme-binding-mediated negative regulation of the tryptophan metabolic enzyme indoleamine 2,3-dioxygenase 1 (IDO1) by IDO2. *Exp Mol Med.* (2014) 46:e121. doi: 10.1038/emm.2014.69

53. Blank CU, Haenen JB, Ribas A, Schumacher TN. Cancer immunology: the “cancer immunogram.” *Science.* (2016) 352:658–60. doi: 10.1126/science.aal2834

54. Nadal E, Masutti B, Domine M, García-Campelo R, Cobo M, Felip E. Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors. *Cancer Immunol Immunother.* (2019) 68:341–52. doi: 10.1007/s00262-019-02310-2

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Mandarinaro, Bellezza, Belladonna, Vannucchi, Gili, Ferri, Lupi, Ludovini, Falabella, Metra, Monandelli, Chiari, Cagini, Stracci, Rolia, Puma, Volpi and Sidoni. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.